ClinicalTrials.gg
CompletedNCT04698603Updated Aug 15, 2023

Clinical Study of GH001 in Depression

A Phase 1/2 interventional study of 5 Methoxy N,N Dimethyltryptamine in Treatment Resistant Depression, Major Depressive Disorder and Depression, sponsored by GH Research Ireland Limited. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2023-08-15.

Sponsored by GH Research Ireland Limited · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Nov 2019, registered Nov 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Depressive Disorder, Treatment-Resistant with a site in Netherlands — 2 open to participants now, 3 under way, 1 of them phase 3. Depressive Disorder, Treatment-Resistant · Netherlands.

Started
2019
with 1 other
Phase 1/2
Only one
of the 10
Registered
6th of 10
by date
Lead sponsor
2 of 10
GH Research Ireland Limited

Among the 10 studies in Depressive Disorder, Treatment-Resistant with a site in Netherlands, this one is one of 2 that started in 2019, is the only one in phase 1/2, and was the 6th registered.

Depressive Disorder, Treatment-Resistant

448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

2 of the 10 studies in Depressive Disorder, Treatment-Resistant with a site in Netherlands are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Depressive Disorder, Treatment-Resistant with a site in Netherlands, or all of them as a file.
02

Study summary

The aim of the study is to investigate the safety of GH001 (containing 5-methoxy-dimethyltryptamine; 5-MeO-DMT), and to investigate its effects on severity of depressive symptoms, and its dose-related psychoactive effects in patients with Treatment-Resistant Depression (TRD).

The study is comprised of two open-label, single-arm study parts where Part A evaluates single doses of GH001 at two dose levels and Part B evaluates a specific individualized dosing regimen of GH001.

Read the detailed description

Phase 1 (Part A):

The primary objective of this study is to assess the safety and tolerability of single doses of GH001 (containing 5-methoxy-dimethyltryptamine; 5-MeO-DMT) in patients with TRD.

The secondary objectives of the study are to assess the effects of single doses of GH001 on various measures of depression, and on dose-related psychoactive effects.

Phase 2 (Part B):

The primary objective of this study is to assess the effects of an individualized dosing regimen of GH001 on the severity of depression.

The secondary objectives of the study are to assess the safety and tolerability of an individualized dosing regimen of GH001 in patients with TRD and its effects on the severity of depression, other measures of depression, and on dose-related psychoactive effects.

Study design: Phase 1/2 study in two parts.

Intervention: In the Phase 1 (Part A), a single dose of GH001 will be administered per patient. Two different dose levels will be investigated with four patients at each dose level. In the Phase 2 (Part B), an individualized dosing regimen will be administered.

In both parts, GH001 will be administered via inhalation.

03

Conditions studied

  • Treatment Resistant Depression
  • Major Depressive Disorder
  • Depression

Keywords

  • Treatment
  • 5-MeO-DMT
  • 5-methoxy-dimethyltryptamine
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a (BMI) in the range of 18.5 and 35.0 kg/m2 (inclusive);
  • Meets the (DSM-5) diagnostic criteria for single-episode major depressive disorder (MDD) or recurrent MDD, without psychotic features confirmed by the Mini-International Neuropsychiatric Interview (MINI);
  • Treatment-Resistant Depression as evaluated by the Antidepressant Treatment History Form - Short Form (ATHF-SF);
  • Has outpatient status at screening and enrolment visits;

Exclusion criteria

Exclusion Criteria:

  • Has a current or prior diagnosis of a psychiatric comorbidity that renders the patient unsuitable for the study according to a study psychiatrist or registered psychologist;
  • Has received any medication within the last 1 month;
  • Has a current medically significant condition (e.g., severe infection) or has a history of a medically significant condition (e.g., medical history of seizure, uncontrolled hypertension, uncontrolled diabetes, severe cardiovascular disease, hepatic or renal failure, etc.) that renders the patient unsuitable for the study according to the medical supervisor's judgment;
  • Takes any medication or other substance that renders the patient unsuitable for the study according to the medical supervisor's judgment;
  • Has a abnormality in physical examination, vital signs, , or clinical laboratory parameters, which renders the patient unsuitable for the study according to the medical supervisor's judgment;
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Phase 1 (Part A): GH001 dose A

    Drug: 5 Methoxy N,N Dimethyltryptamine

  • Experimental
    Phase 1 (Part A): GH001 dose B

    Drug: 5 Methoxy N,N Dimethyltryptamine

  • Experimental
    Phase 2 (Part B): GH001 Individualized Dosing Regimen

    Drug: 5 Methoxy N,N Dimethyltryptamine

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1: The safety and tolerability of GH001 as a combined measure of outcomes 5 to 13.

    Phase 1: The primary endpoint is a binary variable (yes/no) reflecting a combined medical/clinical evaluation of the occurrence of Outcomes 5 to 13. The endpoint will be considered met for any dose level or regimen if the Study Safety Group (SSG) - through a qualitative medical/clinical evaluation - considers that dose level or regimen sufficiently safe and tolerable for potential further clinical development in a subsequent study.

    Time frame: up to 7 days

  2. Phase 2: The effects of GH001 on the severity of depression evaluated by the Montgomery-Asberg Depression Rating Scale (MADRS)

    Phase 2: The assessment is done with the Montgomery-Asberg Depression Rating Scale (MADRS), a diagnostic questionnaire with ten items for measuring the severity of depressive episodes in patients with mood disorders. A higher MADRS score indicates more severe depression, and each item is scored from 0 to 6. The overall score ranges from 0 to 60.

    Time frame: up to 7 days

Secondary outcomes

  1. Phase 1: The effects of GH001 on the severity of depression evaluated by the Montgomery-Asberg Depression Rating Scale (MADRS)

    Phase 1: The assessment is done with the Montgomery-Asberg Depression Rating Scale (MADRS), a diagnostic questionnaire with ten items for measuring the severity of depressive episodes in patients with mood disorders. A higher MADRS score indicates more severe depression, and each item is scored from 0 to 6. The overall score ranges from 0 to 60.

    Time frame: up to 7 days

  2. Phase 2: The safety and tolerability of GH001 as a combined measure of outcomes 5 to 13

    Phase 2: The secondary endpoint is a binary variable (yes/no) reflecting a combined medical/clinical evaluation of the occurrence of Outcomes 5 to 13. The endpoint will be considered met for any dose level or regimen if the Study Safety Group (SSG) - through a qualitative medical/clinical evaluation - considers that dose level or regimen sufficiently safe and tolerable for potential further clinical development in a subsequent study.

    Time frame: up to 7 days

Other outcomes

  1. Type and Frequency of Adverse Events

    Adverse events reported in the study and coded by MedDRA.

    Time frame: up to 7 days

  2. Frequency of clinically significant changes from baseline in the safety laboratory analyses (biochemistry, hematology, urinalysis)

    Safety laboratory analyses are analyses of blood samples (biochemistry, hematology) and urine samples (urinalysis). Changes are defined as any clinically significant change from baseline as determined by the medical supervisor at the site.

    Time frame: up to 7 days

  3. Frequency of clinically significant changes from baseline in Vital Signs

    Vital signs include heart rate (beats per minute), blood pressure (mmHg), respiratory rate (breaths per minute), oxygen saturation (%), and temperature (degrees celsius). Changes are defined as any clinically significant change from baseline as determined by the medical supervisor at the site.

    Time frame: up to 7 days

  4. Frequency of clinically significant changes from baseline in Electrocardiogram (ECG) parameters

    Clinically significant changes in ECG include any significant change in rate or rhythm as determined by the medical supervisor at the site.

    Time frame: up to 3 hours after administration of GH001

  5. Change from baseline in the Brief Psychiatric Rating Scale (BPRS)

    Change from baseline in the Brief Psychiatric Rating Scale (BPRS). A scale to measure psychiatric symptoms. Each symptom is rated 1-7 and a total of 18 symptoms are scored. Combined score ranges from 18 to 126.

    Time frame: up to 7 days

  6. Change from baseline in the Clinician Administered Dissociative States Scale (CADSS)

    Change from baseline in the Clinician Administered Dissociative States Scale (CADSS). The CADSS comprises 19 subjective items, ranging from 0 'not at all' to 4 'extremely. Summed together, these subscales form a total dissociative score. Combined score ranges from 0 to 76.

    Time frame: up to 7 days

  7. Change from baseline in the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Change from baseline in the Columbia-Suicide Severity Rating Scale (C-SSRS). A detailed questionnaire assessing both suicidal behaviour and suicidal ideation. No combined score is created.

    Time frame: up to 7 days

  8. Change from baseline in the Psychomotor Vigilance Test (PVT)

    Change from baseline in the Psychomotor Vigilance Test (PVT). A computerized test assessing the reaction time in response to a visual stimulus. Outcome measures are Response Time and the number of attentional lapses (Response Time ≥ 500 msec).

    Time frame: up to 7 days

  9. Change from baseline in Digit Symbol Substitution Test (DSST)

    Change from baseline in the Digit Symbol Substitution Test (DSST). A computerized test with the task is to match digits with symbols from encoding list. The number of digits correctly encoded within 3 minutes is the performance measure.

    Time frame: up to 7 days

07

Study locations

1 site
  • Clinical Trial Site
    Maastricht, Netherlands
08

References and documents

Publications

  • Reckweg JT, van Leeuwen CJ, Henquet C, van Amelsvoort T, Theunissen EL, Mason NL, Paci R, Terwey TH, Ramaekers JG. A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression. Front Psychiatry. 2023 Jun 20;14:1133414. doi: 10.3389/fpsyt.2023.1133414. eCollection 2023. PubMed 37409159 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Nov 2021, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2020
First posted
Jan 7, 2021
StartActual
Nov 12, 2019
Primary completionActual
Nov 6, 2021
CompletionActual
Nov 6, 2021
Last update
Aug 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04698603
Lead sponsor
GH Research Ireland Limited
Responsible party
Sponsor
First posted
Jan 7, 2021
Start date
Nov 12, 2019
Primary completion
Nov 6, 2021
Completion
Nov 6, 2021
Last update
Aug 15, 2023

Study contacts

GH Research Clinical Team
study director · GH Research Ireland Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methoxydimethyltryptamines

Start the discussion